Spedra Instructions for Erectile Dysfunction: Understanding Your Official Patient Information

• Spedra's official instructions exist in two forms: a technical prescribing document for healthcare professionals and a patient information leaflet supplied with every pack.
• The patient information leaflet, not a general online summary, is the authoritative source for how to take your specific Spedra tablets.
• Spedra's instructions cover dosing, what not to combine it with, and storage, all approved as part of its UK licensing.
• As a prescription-only medicine, genuine access to Spedra requires an appropriate clinical assessment and a valid prescription from a qualified prescriber.

Spedra instructions are the UK-approved directions that come in two forms: a technical prescribing document for healthcare professionals, and the patient information leaflet supplied with every pack, with the leaflet being the main source to follow for your own tablets. Both are part of Spedra's UK licence and cover the same core facts, but they are written for different audiences.

If you have been prescribed Spedra (avanafil) for erectile dysfunction and want to check the official instructions on how to take it safely, this page focuses on the parts that matter in practice: what each document is for, how they differ, dosing and timing, contraindications and interactions, possible side effects, storage, and how to access your own leaflet. That matters because Spedra is a prescription medicine, and using the licensing-approved instructions helps you take the right dose, avoid harmful combinations or outdated advice, and rely on the document that applies to your specific pack rather than a third-party summary.

Where Do Spedra's Official Instructions Come From?

Spedra's official instructions come from the documents approved during its UK licensing process. Every UK-licensed medicine has this kind of formally reviewed documentation attached to it, it is not written independently by a pharmacy or website, and its content has been assessed as part of the medicine gaining its UK marketing authorisation.

This matters because it explains why the instructions carry weight in the first place: they are not marketing copy or a summary someone put together informally, they are the output of a formal regulatory review specific to this exact medicine, strength for strength. The European Medicines Agency assessed Spedra as part of its European authorisation process.

What Is a Summary of Product Characteristics (SmPC)?

A Summary of Product Characteristics, or SmPC, is the technical prescribing document for a medicine, setting out its approved indication, including that Spedra is a PDE5 inhibitor licensed to treat erectile dysfunction in adult men to help achieve and maintain an erection sufficient for satisfactory sexual activity, along with dosing, contraindications, interactions and clinical data in detail. It is part of the formal documentation reviewed as a medicine gains its licence, and it is the source document that other, simpler materials about the medicine are ultimately based on, including how clinical data describe Spedra's effects when sexual stimulation is present.

Who Is the SmPC Written For?

Primarily prescribers and pharmacists, rather than patients directly. It is written in clinical language and assumes a level of medical background, covering detail that is not necessary for a patient to make day-to-day decisions about taking their medicine, which is why a separate, plainer document also exists.

What Is a Patient Information Leaflet (PIL)?

A patient information leaflet is the plain-language document supplied inside every pack of Spedra, written specifically for the person taking the medicine rather than a healthcare professional. It covers what the medicine is for, Spedra's active ingredient, the active substance avanafil, is used to treat erectile dysfunction and helps support an erection when sexual stimulation is present by increasing blood flow to the penis. It does not cause an automatic erection without sexual stimulation, how to take it, possible side effects, and how to store it, drawing on the same approved information as the technical prescribing document but presented for a general reader.

SmPC vs Patient Information Leaflet: What is the Difference?

Both documents reflect the same underlying, licensed information about Spedra, neither one is "more official" than the other, they are simply written for different readers.

What Spedra's Official Instructions Cover

Spedra's official instructions, in either document form, cover four main practical areas: dosing and timing, interactions, side effects, and storage. Each of these is reviewed as part of the medicine's licensing, rather than written independently by any individual pharmacy.

Dosing and Timing Instructions

Spedra is licensed in 50mg, 100mg and 200mg strengths, with 100mg the recommended dose for most men, taken as needed. In some cases, a prescriber may choose a lower dose where appropriate. The licensed instructions describe use approximately 15 to 30 minutes before sexual activity, though it will not work without sexual stimulation, with a maximum of one dose in any 24-hour period. If you are wondering how long Spedra lasts, the medicine may remain effective for several hours, although individual response varies. It can be taken with or without food. A prescriber decides the appropriate strength for each individual, this is not a personal choice made from reading the instructions alone.

Reading the dosing section of your own leaflet is still worthwhile even after a consultation, since it reinforces what you have been told and gives you something to refer back to later rather than relying purely on memory of what was discussed.

What Not to Combine Spedra With

Spedra's instructions specify that it must never be combined with nitrate medicines, due to the risk of a dangerous drop in blood pressure. People with certain severe cardiovascular conditions, including recent cardiovascular events or unstable angina, may be unsuitable for Spedra. Caution is also needed with alpha blockers because of the added blood-pressure interaction risk.

They also identify certain other medicines that make Spedra unsuitable altogether, this includes some HIV medications and antifungals. Certain moderate CYP3A4 inhibitors require a lower maximum dose and may require a longer interval between doses. A full medicines review during your consultation covers this in detail rather than relying on a general list.

The instructions also cover how food affects Spedra: a high-fat meal can delay its onset and reduce its peak plasma concentration, although it does not significantly reduce overall exposure to avanafil. Grapefruit juice should be avoided, and excessive alcohol consumption should be limited, because they can affect response or increase side effects. This kind of detail, food timing, interaction tiers, and the underlying reasoning behind them, is exactly the sort of thing the fuller technical prescribing document sets out in more depth than the patient leaflet needs to for everyday use.

Missed or Skipped Doses

Because Spedra is taken as needed rather than on a fixed daily schedule, there is no "missed dose" to make up in the way there is with a medicine taken every day. If you miss a planned dose, do not take an extra dose to compensate. Take Spedra only as directed for your next planned sexual activity, with no more than one dose in any 24-hour period.

Storage Instructions

Spedra tablets should be kept in their original packaging, at room temperature, away from direct heat and moisture, and out of the sight and reach of children. Any unused or expired tablets should be returned to a pharmacy for safe disposal rather than put in household waste.

How to Find Your Own Spedra Instructions

Your patient information leaflet is included in every pack of Spedra dispensed through a UK-regulated pharmacy. If you have mislaid it, your dispensing pharmacy can confirm the correct leaflet for your specific pack and strength. This is the most reliable route to your own instructions, since it reflects the medicine you have actually been supplied.

It is worth keeping your leaflet somewhere you can find it again, rather than relying on memory of what a consultation covered or a general search if a question comes up later. If you are prescribed a different strength at any point, the leaflet for the new pack should be checked too, since dosing detail is specific to the strength dispensed.

Why Third-Party Summaries Are not a Substitute

A general summary of a medicine, wherever it is published, is a simplified restatement rather than the licensed document itself, and it can lag behind updates or omit detail relevant to your specific situation. Your own patient information leaflet, supplied with your pack, is the version that reflects the currently approved instructions for the exact product you have been given. If anything you have read elsewhere seems to conflict with your leaflet, or with what your prescriber has told you, raise it directly with your pharmacist or prescriber rather than relying on the online summary.

There are a few practical reasons this distinction matters beyond general caution. Approved prescribing information can be updated as new safety data emerges, and an independent summary published elsewhere may not reflect the most recent version. A summary written for a general audience may also simplify or omit detail that's relevant to a specific individual's circumstances, precisely the kind of detail a proper consultation is designed to catch. And because these summaries are written independently of the licensing process, there is no guarantee they accurately reflect the approved document at all, even when well-intentioned.

Common Misconceptions About Spedra's Official Instructions

A few assumptions are worth addressing directly.

"Any website's summary is just as good as reading the leaflet myself." A summary is someone else's interpretation, potentially outdated or incomplete. Your own leaflet reflects the currently approved instructions for your specific pack.

"The patient leaflet is just a legal formality, not really necessary to read." It is written specifically to be useful to you, covering practical points like storage and what to do about side effects, not simply included to meet a regulatory checkbox.

"Technical prescribing information is only useful for doctors, not me." While the SmPC is written primarily for healthcare professionals, understanding that it exists, and that it is the source document behind simpler materials, helps explain why instructions can sometimes read differently across different sources.

"If instructions vary slightly between sources, it does not matter which one I follow." It does matter. Your own patient information leaflet, and guidance from your prescriber, should take precedence over any other source you have come across.

What to Do If You Have Questions About Your Instructions: Ask Your Doctor or Pharmacist

If anything in your patient information leaflet is unclear, or you are unsure how it applies to your specific situation, the right step is to ask your pharmacist or prescriber directly rather than searching for an alternative explanation online. This is a normal part of using prescription-only medicine safely, not an unusual request, and a proper consultation is set up precisely to allow this kind of question to be answered accurately for your individual circumstances.

Getting Spedra in the UK

Because avanafil is a prescription-only medicine, Spedra should only be supplied following an appropriate clinical assessment and valid prescription. A legitimate online pharmacy should require an appropriate clinical assessment and prescription before dispensing Spedra.

Price

Prices are set by individual UK pharmacies and can change. On EveryDayMeds, Spedra is currently listed from £20.69. Prices vary between pharmacies and can change over time. Check the current price with the pharmacy before ordering.

Medical Disclaimer

This page is for general information only and does not constitute medical advice. Avanafil (Spedra) is a prescription-only medicine, and treatment suitability depends on an individual clinical assessment. Your prescriber will determine the appropriate treatment, dose and monitoring for you. This medicine should only be used under the supervision of an appropriately qualified prescriber. Results vary between individuals. Always read the patient information leaflet supplied with your specific pack, since it reflects the currently approved instructions for the exact medicine you have been given. If you have concerns about side effects, possible medicine interactions, or whether Spedra is suitable for you, speak to a pharmacist, prescriber or your GP.